Altria Group (NYSE: MO) has emerged as a surprising stock market winner in 2024, propelled by an impressive earnings rebound. There's a lot for investors to like about this tobacco giant, including the stock's 7% dividend yield as a compelling income opportunity. Let's discuss whether Altria stock is a buy, sell, or hold in 2025 ..read more

While they aren't as sexy as high-flying growth stocks, they can be just as effective at making investors money. The steady income from dividend stocks can also help cushion investors against the inevitable volatility of the stock market. As we head into 2025, it's never too early to begin thinking about which dividend stocks could make sense for your portfolio, especially those with attractive dividend yields ..read more

AbbVie (NYSE: ABBV) today announced updated results from the Phase 1b/2 EPCORE® NHL-2 trial evaluating fixed-duration investigational epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, plus lenalidomide + rituximab (R2) in adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). Among 111 patients with a median follow-up of over two years, overall response rate (ORR) was 96%, and complete response (CR) rate was 87%. The data (Abstract #342 ..read more

CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environmentNORWOOD, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, today announced the dosing of the first patient in the Phase 1 portion of the clinical study of CRB-601 for the treatment of patients with advanced solid tumors (NCT06603844). CRB-601 is a ..read more

AbbVie announced groundbreaking results today from its latest Emotional Impact Report (EIR), a patient survey that provides an understanding of the mental health impacts of a chronic lymphocytic leukemia (CLL) diagnosis. Findings from the survey are the first to report the emotional perspectives of Hispanic, Black, and Asian patients with CLL and their unique experiences and challenges throughout their blood cancer journey.3 The findings were shared during the 66th American Society of Hematology ..read more

Canopy Growth Corporation ("Canopy Growth") (TSX: WEED) (NASDAQ: CGC) and Acreage Holdings, Inc. ("Acreage") (CSE: ACRG.A.U, ACRG.B.U) (OTCQX: ACRHF, ACRDF) today confirmed that Canopy USA, LLC ("Canopy USA") has completed its acquisition (the "Acreage Acquisition") of Acreage. Canopy USA now owns 100% of the issued and outstanding shares of Acreage ..read more

AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy in early Parkinson's disease. Tavapadon is the first and only D1/D5 partial agonist under investigation as a once-daily treatment for Parkinson's disease ..read more

On Monday, AbbVie Inc. (NYSE:ABBV) revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational tavapadon as a flexible-dose monotherapy in early Parkinson's disease. Tavapadon is the first and only D1/D5 partial agonist under investigation as a once-daily treatment for Parkinson's disease. The TEMPO-2 trial evaluated the efficacy, safety and tolerability of a flexible-dose (5 mg to 15 mg, once daily) treatment with tavapadon as a monotherapy in adults with ea ..read more

AbbVie (NYSE: ABBV) today announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, in adult patients with diffuse large B-cell lymphoma (DLBCL) at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH ..read more

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc. (ABBV) and Gilead Sciences, Inc. (GILD), as well as two micro-cap stocks, Air T, Inc. (AIRT) and Fossil Group, Inc. (FOSL ..read more